Pak Fah Yeow International Limited (0239.HK)
HKD 2.24
(-0.44%)
HKD 2.24
(-0.44%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.8 Million HKD | -10.03% |
| 2022 | 7.56 Million HKD | -58.61% |
| 2021 | 18.28 Million HKD | -8.26% |
| 2020 | 19.93 Million HKD | -7.57% |
| 2019 | 21.56 Million HKD | -10.02% |
| 2018 | 23.96 Million HKD | -16.59% |
| 2017 | 28.73 Million HKD | -2.72% |
| 2016 | 29.53 Million HKD | -20.63% |
| 2015 | 37.21 Million HKD | -14.95% |
| 2014 | 43.75 Million HKD | -12.4% |
| 2013 | 49.95 Million HKD | -10.81% |
| 2012 | 56 Million HKD | -22.56% |
| 2011 | 72.32 Million HKD | -0.21% |
| 2010 | 72.47 Million HKD | -3.68% |
| 2009 | 75.23 Million HKD | -30.24% |
| 2008 | 107.85 Million HKD | 20.98% |
| 2007 | 89.15 Million HKD | 3.52% |
| 2006 | 86.12 Million HKD | 6.68% |
| 2005 | 80.73 Million HKD | 0.0% |
| 2004 | - HKD | 0.0% |
| 2003 | - HKD | -100.0% |
| 2002 | 402.91 Thousand HKD | 5.76% |
| 2001 | 380.96 Thousand HKD | -99.33% |
| 2000 | 56.53 Million HKD | 13.79% |
| 1999 | 49.68 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.12 Million HKD | 0.0% |
| 2023 FY | 6.8 Million HKD | -10.03% |
| 2023 Q4 | 6.8 Million HKD | 0.0% |
| 2023 Q2 | 7.56 Million HKD | 0.0% |
| 2022 Q4 | 7.56 Million HKD | 0.0% |
| 2022 Q2 | 15.97 Million HKD | 0.0% |
| 2022 FY | 7.56 Million HKD | -58.61% |
| 2021 Q2 | 19.43 Million HKD | 0.0% |
| 2021 Q4 | 18.28 Million HKD | 0.0% |
| 2021 FY | 18.28 Million HKD | -8.26% |
| 2020 FY | 19.93 Million HKD | -7.57% |
| 2020 Q2 | 18.91 Million HKD | 0.0% |
| 2020 Q4 | 19.93 Million HKD | 0.0% |
| 2019 FY | 21.56 Million HKD | -10.02% |
| 2019 Q4 | 21.56 Million HKD | 0.0% |
| 2019 Q2 | 22.79 Million HKD | 0.0% |
| 2018 FY | 23.96 Million HKD | -16.59% |
| 2018 Q2 | 24.94 Million HKD | 0.0% |
| 2018 Q4 | 21.89 Million HKD | 0.0% |
| 2017 Q4 | 26.66 Million HKD | 0.0% |
| 2017 Q2 | 27.73 Million HKD | 0.0% |
| 2017 FY | 28.73 Million HKD | -2.72% |
| 2016 Q2 | 30.36 Million HKD | 0.0% |
| 2016 Q4 | 27.46 Million HKD | 0.0% |
| 2016 FY | 29.53 Million HKD | -20.63% |
| 2015 FY | 37.21 Million HKD | -14.95% |
| 2015 Q4 | 35.14 Million HKD | 0.0% |
| 2015 Q2 | 37.82 Million HKD | 0.0% |
| 2014 FY | 43.75 Million HKD | -12.4% |
| 2014 Q4 | 43.75 Million HKD | 0.0% |
| 2014 Q2 | 53.42 Million HKD | 0.0% |
| 2013 Q4 | 49.95 Million HKD | 0.0% |
| 2013 FY | 49.95 Million HKD | -10.81% |
| 2013 Q2 | 49.47 Million HKD | 0.0% |
| 2012 Q4 | 56 Million HKD | 0.0% |
| 2012 Q2 | 56.89 Million HKD | 0.0% |
| 2012 FY | 56 Million HKD | -22.56% |
| 2011 Q2 | 71.74 Million HKD | 0.0% |
| 2011 FY | 72.32 Million HKD | -0.21% |
| 2011 Q4 | 72.32 Million HKD | 0.0% |
| 2010 Q2 | 73.29 Million HKD | 0.0% |
| 2010 Q4 | 72.47 Million HKD | 0.0% |
| 2010 FY | 72.47 Million HKD | -3.68% |
| 2009 Q4 | 75.23 Million HKD | 0.0% |
| 2009 FY | 75.23 Million HKD | -30.24% |
| 2008 FY | 107.85 Million HKD | 20.98% |
| 2007 FY | 89.15 Million HKD | 3.52% |
| 2006 FY | 86.12 Million HKD | 6.68% |
| 2005 FY | 80.73 Million HKD | 0.0% |
| 2004 FY | - HKD | 0.0% |
| 2003 FY | - HKD | -100.0% |
| 2002 FY | 402.91 Thousand HKD | 5.76% |
| 2001 FY | 380.96 Thousand HKD | -99.33% |
| 2000 FY | 56.53 Million HKD | 13.79% |
| 1999 FY | 49.68 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 99.8% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 94.344% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 98.523% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -1298.357% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 96.664% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 97.684% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 97.96% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 98.397% |
| SSY Group Limited | 3.37 Billion HKD | 99.798% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 94.895% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 99.091% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.992% |